Pricing Log in Create free account
Friday 6 November 2026 Export TVTX’s income statement to Excel — free account

Travere Therapeutics, Inc.

TVTX Healthcare Biotechnology

Travere Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $490.7 million, up 110.5% from fiscal 2024.

Revenue
+36.2%
EPS
−290.7%
Free cash flow
+6,379.8%
Total debt
+93.8%

Quarter to September 2026, against a year earlier

49.45 0.58 +1.19%
Market cap
$4.7B
P/E
0.0×
Fwd P/E
−145×
Dividend yield
—
F-score
6/9
Altman Z
1.78
Beneish M
−1.74
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Travere Therapeutics, Inc. (TVTX) EV/Sales

Alert me on EV/Sales

As of 6 November 2026, Travere Therapeutics, Inc. (TVTX) trades at a EV/Sales of 7.4×. Over the past ten years it has ranged from 1.3× (March 2020) to 22.0× (March 2015); the current reading is higher than 74% of that period. That is below the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 6.9× 22.88%
FY2024 5.6× 57.25%
FY2023 3.6× (68.44%)
FY2022 11.4× (2.24%)
FY2021 11.6× 100.31%
FY2020 5.8× 149.39%
FY2019 2.3× (40.21%)
FY2018 3.9× (2.15%)
FY2017 4.0× 12.66%
FY2016 3.5× (23.67%)

Quarterly newest first

Period EV/Sales Change
Sep 2026 8.8× (4.49%)
Jun 2026 9.2× 77.12%
Mar 2026 5.2× (25.20%)
Dec 2025 6.9× 37.83%
43 more quarters

Against its own ten years

Low 1.3× High 22.0×
Ten-year median 5.0×
Current reading's percentile 78

EV/Sales against peers

Company EV/Sales
EWTX Edgewise Therapeutics, Inc. compare n/m
DFTX Definium Therapeutics, Inc. compare n/m
ERAS Erasca, Inc. compare n/m
MANE Veradermics Incorporated compare n/m
LEGN Legend Biotech Corporation Sponsored ADR compare 2.9×
TVTX Travere Therapeutics, Inc. 7.4×
CRSP CRISPR Therapeutics AG compare 125×
COGT Cogent Biosciences, Inc. compare 209×
DNTH Dianthus Therapeutics, Inc. compare 1,515×
Biotechnology industry median 9.0×
Healthcare sector median 3.6×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on TVTX